MX383492B - Comprimidos probióticos bicapa de doble liberación. - Google Patents

Comprimidos probióticos bicapa de doble liberación.

Info

Publication number
MX383492B
MX383492B MX2016016773A MX2016016773A MX383492B MX 383492 B MX383492 B MX 383492B MX 2016016773 A MX2016016773 A MX 2016016773A MX 2016016773 A MX2016016773 A MX 2016016773A MX 383492 B MX383492 B MX 383492B
Authority
MX
Mexico
Prior art keywords
different
probiotic
release
probiotics
biotic
Prior art date
Application number
MX2016016773A
Other languages
English (en)
Spanish (es)
Other versions
MX2016016773A (es
Inventor
Anthony Blanch
Timothy Gamble
Original Assignee
Probi Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Usa Inc filed Critical Probi Usa Inc
Publication of MX2016016773A publication Critical patent/MX2016016773A/es
Publication of MX383492B publication Critical patent/MX383492B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016016773A 2014-07-01 2015-06-29 Comprimidos probióticos bicapa de doble liberación. MX383492B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019717P 2014-07-01 2014-07-01
PCT/US2015/038254 WO2016003870A1 (en) 2014-07-01 2015-06-29 Bi-layer dual release probiotic tablets

Publications (2)

Publication Number Publication Date
MX2016016773A MX2016016773A (es) 2017-06-30
MX383492B true MX383492B (es) 2025-03-04

Family

ID=55019868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016773A MX383492B (es) 2014-07-01 2015-06-29 Comprimidos probióticos bicapa de doble liberación.

Country Status (17)

Country Link
US (1) US10799541B2 (enExample)
EP (1) EP3164145A4 (enExample)
JP (1) JP2017520577A (enExample)
KR (1) KR20170021350A (enExample)
CN (1) CN106535909A (enExample)
AP (1) AP2016009641A0 (enExample)
AU (1) AU2015284425B2 (enExample)
BR (1) BR112016031000B1 (enExample)
CA (1) CA2951739C (enExample)
CL (1) CL2016003306A1 (enExample)
MA (1) MA40071A (enExample)
MX (1) MX383492B (enExample)
PH (1) PH12016502463A1 (enExample)
RU (1) RU2736823C2 (enExample)
SG (1) SG11201610250WA (enExample)
WO (1) WO2016003870A1 (enExample)
ZA (1) ZA201608433B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN108066296B (zh) * 2016-11-11 2020-11-17 南京益恒寿生命科技有限公司 一种生物学活性组分结肠靶向组合物及其应用
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
US20210069262A1 (en) * 2018-01-05 2021-03-11 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
EP3556226B1 (de) * 2018-04-20 2021-01-20 Raab Vitalfood GmbH Komplex-synbiotikum zum aufbau einer gesunden darmflora
KR102770563B1 (ko) 2018-06-18 2025-02-21 프로비 에이비 락토바실러스 플란타룸 조성물 및 이의 용도
US20210113633A1 (en) 2018-06-18 2021-04-22 Probi Ab Probiotic compositions and uses thereof
WO2020056298A1 (en) 2018-09-13 2020-03-19 Assembly Biosciences, Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
US20220175893A1 (en) * 2019-03-05 2022-06-09 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
GB201905386D0 (en) 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
GB201908154D0 (en) 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
GB201908706D0 (en) 2019-06-18 2019-07-31 Probi Ab Lactobacillus compositions and uses thereof
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
CN117159485A (zh) * 2023-08-11 2023-12-05 江中药业股份有限公司 一种益生菌香口丸及其制备方法
WO2026017258A1 (en) 2024-07-18 2026-01-22 Probi Ab Lacticaseibacillus compositions and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037953A (ja) * 1983-08-11 1985-02-27 Herusu Eido:Kk カルシウムを主成分とする栄養補助食品
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DE59706697D1 (de) * 1997-12-19 2002-04-25 Merck Patent Gmbh Mehrschichttablette enthaltend probiotische Mikroorganismen wie z.B. Lactobacilli oder Bifidobakterien
JP2000302694A (ja) 1999-04-16 2000-10-31 Fuyuki Mitsuyama 医食兼用物質
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
EP1151673A3 (en) 2000-05-03 2002-01-02 Societe Des Produits Nestle S.A. Confectionery product having a filling
JP5186077B2 (ja) 2000-12-18 2013-04-17 プロバイオヘルス・エルエルシー ラクトバシラス−カゼイｋｅ０１株から得られたプロバイオティック化合物
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
AU2002245979A1 (en) 2001-04-05 2002-10-21 Universite Laval Process for making protein delivery matrix and uses thereof
US6627220B2 (en) 2001-07-13 2003-09-30 Scolr, Inc. Tablets containing heat sensitive materials and method for forming thereof
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
CA2778208C (en) 2001-09-28 2015-11-10 Tntgamble Inc. Delivery system for biological component
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US20030175295A1 (en) 2002-03-15 2003-09-18 Richard Ticktin Composition and method for reducing odors from metabolic processes
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20050266069A1 (en) 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20060188563A1 (en) 2003-03-27 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
EP1661983B1 (en) 2003-08-21 2011-01-05 Otsuka Pharmaceutical Co., Ltd. Lactic acid bacteria having mucosal immunopotentiation effect
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
US20080286253A1 (en) 2004-02-09 2008-11-20 Transfert Plus Societe En Commandite Composition Comprising Polymeric Material And Uses Thereof
US20050260181A1 (en) 2004-03-05 2005-11-24 Immunopath Profile, Inc. Compositions and methods for tissue repair
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
GB0410785D0 (en) 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
WO2005115341A2 (en) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
DE102004026706A1 (de) 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
US20060062773A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal gastrointestinal flora
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
ATE515198T1 (de) 2005-05-18 2011-07-15 Dsm Ip Assets Bv Zusammensetzung für die enterale verabreichung von mikroorganismen
ES2526094T3 (es) 2005-09-29 2015-01-05 Merck Patent Gmbh Procedimiento para estabilizar formas de administración farmacéuticas que contienen microorganismos
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
PL1962873T3 (pl) 2005-12-14 2014-03-31 Oxthera Intellectual Property Ab Kompozycje farmaceutyczne zawierające bakterie zmniejszające ilość szczawianu
US20070184111A1 (en) 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
EP2409691A1 (en) 2007-04-04 2012-01-25 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
WO2009020595A2 (en) * 2007-08-03 2009-02-12 Shaklee Corporation Nutritional supplement system
US20100239682A1 (en) 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20100226995A1 (en) 2007-11-12 2010-09-09 Debrouse Daniel R Microencapsulated bioactive agents for oral delivery and methods of use thereof
US20110223248A1 (en) 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
EP2244593B1 (en) 2008-01-24 2015-06-10 Nestec S.A. Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule
CN102014926A (zh) 2008-05-01 2011-04-13 宝洁公司 用于治疗炎性肠病的方法和试剂盒
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
CN102123604A (zh) * 2008-06-24 2011-07-13 Wm.雷格利Jr.公司 益生菌口香糖的制造方法
WO2010028489A1 (en) 2008-09-15 2010-03-18 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
KR20110097829A (ko) * 2008-11-14 2011-08-31 포톨라 파마슈티컬스, 인코포레이티드 낮은 ｐＨ에서 불량한 수용해도를 갖는 이온화가능한 활성제의 제어 방출을 위한 고체 조성물, 및 그의 사용 방법
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
EP2381799B1 (en) 2009-01-27 2018-08-08 Probiotical S.p.a. Chocolate flavoured probiotic supplement
KR20110124780A (ko) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
JP2012520325A (ja) 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プレバイオティックオリゴ糖
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
US20120087902A1 (en) * 2009-07-20 2012-04-12 Bracco S.P.A. Therapeutic Use Of Probiotics
CN102470152A (zh) 2009-07-30 2012-05-23 丹尼斯科公司 用于治疗内毒素血症的乳酸菌和双歧杆菌
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
EP2571894A1 (en) 2010-05-19 2013-03-27 North Carolina State University Compositions and methods for the delivery of therapeutic peptides
US20140154312A1 (en) 2010-09-17 2014-06-05 Monica Gulati Oral targetted drug delivery system
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
ES2561253T3 (es) * 2011-03-17 2016-02-25 Probiotical S.P.A. Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
ES2660775T3 (es) 2011-05-16 2018-03-26 Belano Medical Ag Nuevas bacterias del ácido láctico y composiciones que las contienen contra los resfriados bacterianos
CN202427429U (zh) * 2012-01-09 2012-09-12 北京大北农科技集团股份有限公司 一种多层微囊制备设备
US20130295227A1 (en) 2012-05-01 2013-11-07 Robbert H. ter Haar Composition Comprising a Sensitive Ingredient
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
EP2958575B1 (en) * 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
EP2968187A4 (en) * 2013-03-14 2016-08-17 Therabiome Llc TARGETED GASTROINTESTINAL RELEASE OF PROBIOTIC ORGANISMS AND / OR THERAPEUTICS

Also Published As

Publication number Publication date
RU2017102952A (ru) 2018-08-01
CL2016003306A1 (es) 2017-06-09
RU2736823C2 (ru) 2020-11-20
BR112016031000B1 (pt) 2022-01-25
EP3164145A4 (en) 2018-01-17
AU2015284425B2 (en) 2021-04-01
CA2951739A1 (en) 2016-01-07
AU2015284425A1 (en) 2017-01-05
MA40071A (fr) 2016-01-07
WO2016003870A1 (en) 2016-01-07
KR20170021350A (ko) 2017-02-27
JP2017520577A (ja) 2017-07-27
RU2017102952A3 (enExample) 2019-02-01
CN106535909A (zh) 2017-03-22
US20170100442A1 (en) 2017-04-13
AP2016009641A0 (en) 2016-12-31
US10799541B2 (en) 2020-10-13
BR112016031000A2 (enExample) 2017-08-22
ZA201608433B (en) 2023-05-31
CA2951739C (en) 2023-09-19
EP3164145A1 (en) 2017-05-10
MX2016016773A (es) 2017-06-30
PH12016502463A1 (en) 2017-04-10
SG11201610250WA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
MX383492B (es) Comprimidos probióticos bicapa de doble liberación.
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
IL262581B1 (en) Production methods, preparations and medical applications of drugs containing cannabis for oral administration
EP3600563C0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN D3 AND HYALURONIC ACID
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
EP3389628A4 (en) PHARMACEUTICAL FORMULATIONS OF MOUSE CHEESE TABLETS
IL273740A (en) Oral pharmaceutical formulation containing bacteria
IL261982A (en) A prophylactic and therapeutic preparation based on peroxaphthalate, especially a pharmaceutical preparation
PL3319620T3 (pl) Bakteria lactobacillus paracasei do produkcji sprzężonego kwasu linolowego, zawierające ją preparaty odżywcze i farmaceutyczne oraz ich zastosowania
IL250267B (en) History of indolizine, their preparation and pharmaceutical preparations containing them
EP3275452A4 (en) Pharmaceutical composition containing silibinin
PT3102187T (pt) Composições farmacêuticas estáveis contendo sitagliptina sob a forma de comprimidos de libertação imediata
IL273704A (en) Pharmaceutical bilayer tablet formulations
IL272806B1 (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
LT3318259T (lt) Stabili farmacinė kompozicija, skirta peroraliniam vartojimui
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
PL3525769T3 (pl) Tabletka ulegająca rozpadowi w jamie ustnej zawierająca burlulipazę i wytworzona z niej kompozycja farmaceutyczna
PH12016500693B1 (en) Slow-release solid oral compositions
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
MX2022013541A (es) Composiciones de acido gamma-poliglutamico y zinc.
EP3210614A4 (en) Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
EP3162368A4 (en) Pharmaceutical composition for oral administration
PL3344281T3 (pl) Kompozycja farmaceutyczna zawierająca najmniej jeden enzym trawienny do stosowania w sztucznym żywieniu
EP3177279A4 (en) Oral composition for delivery of drugs and other substances
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin